Santarus boosted by positive PhIII; Tetraphase touts PhII antibiotic data for lead program; Atox drug hits FDA's fast track;

Conversations on Twitter :

 @FierceBiotech: D-Day for Sanofi multiples cerlosis drug Aubagio as deep R&D cuts loom. Story | Follow @FierceBiotech

 @JohnCFierce: Lundbeck, Otsuka scramble to get antipsychotic back on FDA track--(competing with Alkermes). Article | Follow @JohnCFierce

 @RyanMFierce: My take on Illumina's alliance with Partners HealthCare to combine sequencing and software. Story | Follow @RyanMFierce

> Shares of Santarus were boosted after the biotech reported that its experimental treatment for traveler's diarrhea successfully beat out a placebo in Phase III. On average patients taking rifamycin SV MMX no longer suffered from diarrhea after an average of 46 hours. Patients on a placebo continued to suffer to 68 hours. Story

> 2010 Fierce 15 winner Tetraphase says its lead antibiotic delivered solid results in a mid-stage, 143-patient comparison study. In the three-arm study, which included a group of patients receiving Merck's ($MRK) Invanz and two doses of TP-434, Tetraphase says all three arms demonstrated cure rates of 93% to 100%. Watertown, MA-based Tetraphase is one of several biotechs developing new antibiotics. Release

> Israel's Atox Bio won fast-track designation from the FDA for AB103, its program to combat flesh-eating bacteria. Story

> Shares of Cell Therapeutics ($CTIC) bumped up after the U.S. biotech outlined plans to launch its cancer drug Pixuvri in several Nordic countries. Story

> Australia's Prana Biotechnology, a penny stock company, got a boost when an independent committee recommended continued work on its Alzheimer's drug PBT2. Story

Pharma News

 @FiercePharma: Sanofi workers to strike as day of reckoning nears. More | Follow @FiercePharma

> Merck's Singulair sales free-fall 90% in 4 weeks. Article

> Roche loses patent fight in India as Novartis fights on. Report

> Pfizer's Prevenar 13 gets a shot in the arm with WHO approval. Story

Medical Device News

 @FierceMedDev: J&J has settled the first three lawsuits involving failure of its ASR hip implants. Thousands more to come. Release | Follow @FierceMedDev

 @MarkHFierce: bioMerieux got slapped with an FDA warning letter for quality violations regarding a NC Dx manufacturing facility. Warning Letter | Follow @MarkHFierce

 @DamianFierce: Berkeley's Ekso Bionics is looking to expand the use of its robotic walking aid. Report | Follow @DamianFierce

> IntraPace preps anti-obesity device for U.S. regulatory path. More

> PrimeraDx snags CE marks for assays. News

Biomarkers News

> Janssen's Remicade attacks inflammation to beat depression. Article

> Increased antibody levels tag raised rheumatoid arthritis risk. Story

> Researchers develop genetic test to fine-tune warfarin dose. Item

> Breast cancer protein pinpoints survival chances. More

Drug Delivery News

> Hopkins cracks blood-brain barrier with nanobeads. More

> Sublingual opioid addiction therapy moves closer to market. Report

> Silence breaks out with preclinical data on Atu111. Story

> InSite eyes next-generation DuraSite delivery. Article

> Anti-HIV vaginal ring shows hints of efficacy. More

> AZ goes Down Under for cancer conjugate deal. Item

And Finally... MedImmune is hinting that it may expand its HQ facilities. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.